Search results
Showing results for
Dr. Jane Walker, Department of Psychiatry, is the 2018 recipient of the Don R. Lipsitt award.
Neuroimaging Analysis for Clinical Translation
- Alzheimer's
- Brain function
- Brain imaging
- Dementia
- Evaluation
- Functional imaging
- Magnetic Resonance Imaging (MRI)
- Medical co-morbidity
- Medical imaging
- Neuroimaging
- Neuroscience
We develop neuroimaging analysis methods that support the translation of brain imaging into clinical practice. We focus on robust, interpretable tools that enable meaningful use of neuroimaging data for understanding, diagnosis, and monitoring of brain disorders.
Modifying Dementia Risk
Modifiable risk factors for dementia include those factors that can be altered or changed in some way (modified), usually for the better. The Lancet 2020 commission (Livingston et al., 2020) advocated that there are 12 risk factors which can be potentially modified to prevent or slow the progression of dementia. These are less education, hypertension, obesity, alcohol, traumatic brain injury (TBI), hearing loss, smoking, depression, physical inactivity, social isolation, diabetes and air pollution.
Early Adversity & Brain Health
Blossom Early Adversity & Brain Health Programme is dedicated to investigating the effects of early life adversity on later life brain health, including mental health, cognition and dementia.
Heart and Brain Ageing Group
- Alzheimer's
- Brain function
- Brain imaging
- Cognitive
- Dementia
- Magnetic Resonance Imaging (MRI)
- Medical co-morbidity
- Medicine
Nearly a third of dementia cases can be prevented by modifying our lifestyle, in particular our cardiovascular health. While we know that “what’s good for the heart is good for the brain”, we still don’t entirely know why. Our group investigates this heart-brain link in detail, by studying how the health of our heart and large blood vessels affect the brain and memory as we grow older.
Computational and Molecular Neuroscience
The Computational and Molecular Neuroscience Research Group is a multidisciplinary laboratory specialized on the intersection of computational and molecular methods to study neurodegenerative diseases. The computational methods entail mainly Artificial Intelligence and Bioinformatics, while the molecular side brings state of the art multi-culture iPSC models of disease and high throughput screening. We are especially interested in Alzheimer's and Parkinson’s disease, and how we can use the computational and molecular methods mentioned above to find new drug targets and therapies. We have three main areas of activity: better understanding disease to identify new therapies; discovering biomarkers to enable preventative trials; and validating findings in advanced cell models of disease.
Translational Neuroimaging
- Alzheimer's
- Brain
- Brain function
- Brain imaging
- Clinical trial
- Cognitive models
- Cohorts
- Dementia
- Empirical
- Functional imaging
- Genetics
- Magnetic Resonance Imaging (MRI)
- Medical imaging
- Neuroimaging
- Neurology
- Neuroscience
- Parkinson's
- Risk factors
- Whitehall Study
Neuroimaging provides a window into the living brain, and is an increasingly vital experimental medicine tool for neuro-psychiatric disease. With a particular focus on early and pre-clinical disease, we explore how the brain changes before symptoms take hold.